{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% CI could not be estimated. Follow-up was restricted to 6 months post transplant.","groupId":"OG000","lowerLimit":"92","upperLimit":"NA","value":"191"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Progression-free Survival (PFS) defined as the time from transplantation to the occurrence of the event that was death or first recurrence of progressive disease (PD) by IMWG criteria. PD was defined as an Increase of ≥25% from the lowest response value in any one or more of the following: 1)Serum M-component and/or (the absolute increase must be ≥0.5 g/dL), 2)Urine M-component and/or (the absolute increase must be ≥200 mg/24 hr), 3)In patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be \\>10 mg/dL, 4)Bone marrow plasma cell percentage; the absolute percentage must be ≥10%, 5)Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas and/or 6)Development of hypercalcaemia that can be attributed solely to the plasma cell proliferative diso","dispersionType":"95% Confidence Interval","groups":[{"description":"Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.","id":"OG000","title":"IV Busulfan"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.","reportingStatus":"POSTED","timeFrame":"6 Months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Days"}